Lorlatinib
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Lorlatinib
- Pharmacist Assessment Report
- Lorlatinib: From ALK-Positive Non-Small Cell Lung Cancer to fibromatosis, gingival
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Lorlatinib: From ALK-Positive Non-Small Cell Lung Cancer to fibromatosis, gingival
One-Sentence Summary
Lorlatinib is an oral kinase inhibitor originally used to treat non-small cell lung cancer (NSCLC) and lung cancer. The TxGNN model ranks gingival fibromatosis as its top predicted new indication (score 0.9981), but no clinical trials and no publications support this prediction. It is a computational signal only and should not be treated as actionable evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Non-small cell lung cancer; lung cancer (the ARTG indication text is not available in the data compiled for this report) |
| Predicted New Indication | Fibromatosis, gingival |
| TxGNN Prediction Score | 0.9981 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for lorlatinib is not available in the data compiled for this report. From the literature retrieved, lorlatinib is a brain-penetrant, third-generation ALK/ROS1 tyrosine kinase inhibitor. It is used in ALK-positive advanced NSCLC, where it has Phase 3 evidence (the CROWN study).
The review found no identifiable link between ALK/ROS1 inhibition and gingival fibromatosis. The high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Gingival fibromatosis is not known to be driven by ALK or ROS1 signalling.
The other top-ranked predictions are similarly weak:
- Fibroma of lung, hamartoma of lung, lung benign neoplasm and pulmonary sulcus neoplasm likely score highly because the TxGNN model (deep learning) learned similarities between these diseases and the approved lung cancer indication, which may not reflect biological evidence. They are not known to be ALK-driven. The publications retrieved for lung benign neoplasm concern ALK-positive NSCLC and cannot be transferred to benign tumours.
- Lung germ cell tumour has no direct evidence. The literature relates to ALK-driven neuroblastoma (including a Phase 1 trial), ALK-fusion glioma and pulmonary large-cell neuroendocrine carcinoma. This suggests activity in ALK-driven tumours generally, not in germ cell tumours.
- Inclusion body myopathy with Paget disease, junctional epidermolysis bullosa and the leukomelanoderma syndrome have no mechanistic link to ALK signalling. The publications retrieved for the last of these are adverse-event reports, not therapeutic evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for gingival fibromatosis.
Literature Evidence
Currently no related literature available for gingival fibromatosis.
The only literature found relates to lower-ranked predictions, and all of it concerns ALK-driven cancers or lorlatinib adverse events:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33207094 | 2020 | RCT (Phase 3) | N Engl J Med | First-line lorlatinib vs crizotinib in advanced ALK-positive NSCLC (CROWN) |
| 38819031 | 2024 | RCT (Phase 3, 5-year follow-up) | J Clin Oncol | Long-term progression-free survival and intracranial benefit of lorlatinib vs crizotinib in NSCLC |
| 42217582 | 2026 | Phase 3 update | Ann Oncol | 7-year CROWN update confirming long-term outcomes |
| 36535300 | 2023 | RCT subanalysis | Lancet Respir Med | 3-year CROWN data, including intracranial activity |
| 39368244 | 2024 | Network meta-analysis | Lung Cancer | Lorlatinib compared with other ALK inhibitors as first-line therapy |
| 37012551 | 2023 | Phase 1 trial | Nat Med | Lorlatinib with or without chemotherapy in ALK-driven relapsed or refractory neuroblastoma |
| 37934724 | 2023 | Case report | Am J Case Rep | Pathological complete response after neoadjuvant lorlatinib in advanced ALK-positive lung cancer |
| 38554546 | 2024 | Review | Lung Cancer | Practical guide to managing lorlatinib adverse events |
These papers support lorlatinib’s use in ALK-positive NSCLC. They do not support the predicted new indication.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 12091J | Lorviqua | Tablet 100 mg (oral) | Not available in the data compiled for this report |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (ALK/ROS1 tyrosine kinase inhibitor), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the PI. The literature highlights lipid profile (hypercholesterolaemia and hypertriglyceridaemia), central nervous system effects and pulmonary symptoms |
| Handling Protection | Please refer to the PI and local institutional policy for oral anticancer agents |
Safety Considerations
Warnings and contraindications are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.
Drug interactions: A screen identified 100 potential interactions. The main ones from the listed entries are:
- Major: dexamethasone, clarithromycin
- Moderate (examples): hydrocortisone, betamethasone, triamcinolone, bupropion, aprepitant, cimetidine, morphine, alosetron, eliglustat, dronabinol, naldemedine, naloxegol
- Moderate (glucose-lowering agents): chlorpropamide, glimepiride, dapagliflozin, empagliflozin, saxagliptin, linagliptin
Safety signals from the retrieved literature (case-level or observational):
- Hyperlipidaemia and complex dyslipidaemia
- Acute respiratory distress syndrome
- Pulmonary toxicity when given concurrently with anti-GD2 antibody therapy
- Drug-induced Sweet syndrome
- Metabolic effects such as weight gain
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, gingival fibromatosis, has a high model score but no clinical trials, no publications and no plausible mechanistic link to ALK/ROS1 inhibition. Evidence is L5 (model prediction only). Phase 3 evidence exists only for the already-approved NSCLC indication and cannot be extended to this condition.
To proceed, the following is needed:
- Detailed mechanism of action data, to test whether any biological rationale exists
- Preclinical or mechanistic evidence linking ALK/ROS1 signalling to gingival fibromatosis
- The ARTG approved indication text and TGA Product Information, to complete the safety screen
- If a lung-related use is of interest, a focused evaluation of lung hilum carcinoma restricted to ALK-positive disease, which falls largely within the existing NSCLC indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.